Residual symptoms and functioning in depression, does the type of residual symptom matter? A post-hoc analysis

BMC Psychiatry

Volumn 13, Issue , 2013, Pages

  Romera, Irene ^a,b   Pérez, Víctor ^c   Ciudad, Antonio ^a   Caballero, Luis ^d   Roca, Miguel ^e   Polavieja, Pepa ^a   Gilaberte, Inmaculada ^a  

^a Department of Clinical Research Lilly SA ^*  (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^e Hospital Joan March   (Spain)

Author keywords

Functioning; Major depression; Residual symptoms

Indexed keywords

SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGITATION; ANXIETY DISORDER; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HAMILTON SCALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONOTHERAPY; OBSERVATIONAL STUDY; OUTPATIENT CARE; POST HOC ANALYSIS; PSYCHOSOMATICS; SOCIAL STATUS; SUICIDE; SYMPTOM; VISUAL ANALOG SCALE;

ACTIVITIES OF DAILY LIVING; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84873505316     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-13-51     Document Type: Article

References (31)

1. Romera I, Perez V, Menchón JM, Delgado-Cohen H, Polavieja P, Gilaberte I. Social and occupational functioning impairment in patients in partial versus complete remission of a major depressive disorder episode. A six-month prospective epidemiological study. Eur Psychiatry 2010, 25:58-65.
2. Zimmerman M, Posternak MA, Chelminski I. Heterogeneity among depressed outpatients considered to be in remission. Compr Psychiatry 2007, 48:113-117. 10.1016/j.comppsych.2006.10.005, 17292700.
3. Paykel ES, Ramana R, Cooper Z, Hayhurst H, Kerr J, Barocka A. Residual symptoms after partial remission: an important outcome in depression. Psychol Med 1995, 25:1171-1180. 10.1017/S0033291700033146, 8637947.
4. Pintor L, Torres X, Navarro V, Matrai S, Gastó C. Is the type of remission after a major depressive episode an important risk factor to relapses in a 4-year follow up?. J Affect Disord 2004, 82:291-296. 10.1016/j.jad.2003.11.008, 15488260.
5. Judd LL, Akiskal HS, Maser JD, Zeller PJ, Endicott J, Coryell W, Paulus MP, Kunovac JL, Leon AC, Mueller TI, Rice JA, Keller MB. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord 1998, 50:97-108. 10.1016/S0165-0327(98)00138-4, 9858069.
6. Nierenberg AA, Husain MM, Trivedi MH, Fava M, Warden D, Wisniewski SR, Miyahara S, Rush AJ. Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychol Med 2010, 40:41-50. 10.1017/S0033291709006011, 19460188.
7. Romera I, Pérez V, Menchón JM, Polavieja P, Gilaberte I. Optimal cutoff point of the Hamilton Rating Scale for Depression according to normal levels of social and occupational functioning. Psychiatry Res 2011, 30:133-137.
8. Miller IW, Keitner GI, Schatzberg AF, Klein DN, Thase ME, Rush AJ, Markowitz JC, Schlager DS, Kornstein SG, Davis SM, Harrison WM, Keller MB. The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine. J Clin Psychiatry 1998, 59:608-619. 10.4088/JCP.v59n1108, 9862607.
9. Keller MB. Past, present, and future directions for defining optimal treatment outcome in depression: remission and beyond. JAMA 2003, 289:3152-3160. 10.1001/jama.289.23.3152, 12813121.
10. Ciudad A, Alvarez E, Roca M, Baca E, Caballero L, Garcia De Polavieja P, Casillas M, Valladares A, Gilaberte I. Early Response and Early Remission as Predictors of Good Outcome of a Depressive Episode. J Clin Psychiatry 2012, 73:185-191. 10.4088/JCP.10m06314, 22053897.
11. American Psychiatric Association DSM-TR Diagnostic and Statistic Manual of Mental Health Disorders Text Revision, ed. 4 2000, Washington: American Psychiatric Association, American Psychiatric Association.
12. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960, 23:56-62. 10.1136/jnnp.23.1.56, 495331, 14399272.
13. Guy W. 1976 ECDEU assessment manual for psychopharmacology 1976, 313-331. Rockville, Md. U. S: Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs.
14. Goldman HH, Skodol AE, Lave TR. Revising axis V for DSM-IV: a review of measures of social functioning. Am J Psychiatry 1992, 149:1148-1156.
15. Spitzer RL, Gibbon M, Endicott J, Mental Health Status, Functioning and Disability Measures. In Handbook of psychiatric measures Global Assessment Scale (GAS), Global Assessment of Functioning (GAF) Scale, Social and Occupational Functioning Assessment Scale (SOFAS) 2000, 96-100. Washington DC: American Psychiatric Association: 1st edition. Edited by First MB, Mental Health Status, Functioning and Disability Measures. In Handbook of psychiatric measures.
16. Dombrovski AY, Cyranowski JM, Mulsant BH, Houck PR, Buysse DJ, Andreescu C, Thase ME, Mallinger AG, Frank E. Which symptoms predict recurrence of depression in women treated with maintenance interpersonal psychotherapy?. Depress Anxiety 2008, 25:1060-1066. 10.1002/da.20467, 2705944, 18781665.
17. DeLoach LJ, Higgins MS, Caplan AB, Stiff JL. The visual analog scale in the immediate postoperative period: intrasubject variability and correlation with a numeric scale. Anesth Analg 1998, 86:102-106.
18. Romera I, Fernández-Pérez S, Montejo AL, Caballero F, Caballero L, Arbesú J, Delgado-Cohen H, Desaiah D, Polavieja P, Gilaberte I. Generalized anxiety disorder, with or without co-morbid major depressive disorder, in primary care: prevalence of painful somatic symptoms, functioning and health status. J Affect Disord 2010, 127:160-168. 10.1016/j.jad.2010.05.009, 20541811.
19. Katz J, Melzack R. Measurement of pain. Surg Clin North Am 1999, 79:231-252. 10.1016/S0039-6109(05)70381-9, 10352653.
20. Bodian CA, Freedman G, Hossain S, Eisenkraft JB, Beilin Y. The visual analog scale for pain: clinical significance in postoperative patients. Anesthesiology 2001, 95:1356-1361. 10.1097/00000542-200112000-00013, 11748392.
21. Hosmer DW, Lemeshow S. Goodness-of-fit test for the multiple logistic regression model. Communication in Statistics - Theory and Methods 1980, 9:1043-1069. 10.1080/03610928008827941, 23407212.
22. Iovieno N, van Nieuwenhuizen A, Clain A, Baer L, Nierenberg AA. Residual symptoms after remission of major depressive disorder with fluoxetine and risk of relapse. Depress Anxiety 2011, 28:137-144. 10.1002/da.20768, 21284066.
23. McClintock SM, Husain MM, Wisniewski SR, Nierenberg AA, Stewart JW, Trivedi MH, Cook I, Morris D, Warden D, Rush AJ. Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication. J Clin Psychopharmacol 2011, 31:180-186. 10.1097/JCP.0b013e31820ebd2c, 21346613.
24. Conradi HJ, Ormel J, de Jonge P. Presence of individual (residual) symptoms during depressive episodes and periods of remission: a 3-year prospective study. Psychol Med 2011, 8:1-10.
25. Benvenuti A, Rucci P, Calugi S, Cassano GB, Miniati M, Frank E. Relationship of residual mood and panic-agoraphobic spectrum phenomenology to quality of life and functional impairment in patients with major depression. Int Clin Psychopharmacol 2010, 25:68-74. 10.1097/YIC.0b013e328333ee8e, 3387571, 20061961.
26. Taylor DJ, Walters HM, Vittengl JR, Krebaum S, Jarrett RB. Which depressive symptoms remain after response to cognitive therapy of depression and predict relapse and recurrence?. J Affect Disord 2010, 123:181-187. 10.1016/j.jad.2009.08.007, 2860061, 19733912.
27. Bertschy G, Haffen E, Gervasoni N, Gex-Fabry M, Osiek C, Marra D, Aubry JM, Bondolfi G. Self-rated residual symptoms do not predict 1-year recurrence of depression. Eur Psychiatry 2010, 25:52-57.
28. Roca M, García-Toro M, García-Campayo J, Vives M, Armengol S, García-García M, Asensio D, Gili M. Clinical differences between early and late remission in depressive patients. J Affect Disord 2011, 134:235-241. Epub 2011, 10.1016/j.jad.2011.05.051, 21676465.
29. Ozyüksel B, Uluǧ B. [The association between disability and residual symptoms in depressive patients: a 3-month follow-up.]. Turk Psikiyatri Derg 2007, 18:323-332.
30. Dombrovski AY, Mulsant BH, Houck PR, Mazumdar S, Lenze EJ, Andreescu C, Cyranowski JM, Reynolds CF. Residual symptoms and recurrence during maintenance treatment of late-life depression. J Affect Disord 2007, 103:77-82. 10.1016/j.jad.2007.01.020, 2680091, 17321595.
31. Yang H, Chuzi S, Sinicropi-Yao L, Johnson D, Chen Y, Clain A, Baer L, McGrath PJ, Stewart JW, Fava M, Papakostas GI. Type of residual symptom and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine. Eur Arch Psychiatry Clin Neurosci 2010, 260:145-150. 10.1007/s00406-009-0031-3, 19572158.